Anna joined FAIRR in November 2023 as the Senior ESG Analyst in the Research & Engagements team focusing on the Antibiotics and Health workstreams. Her work on the Animal Pharmaceutical and Restaurant Antibiotics engagements supports investor members and corporates to understand the risks associated with the overuse of antibiotics in intensive animal agriculture and drive positive change at key stages of the animal protein supply chain.
Working at FAIRR
Anna provides in-depth research and analysis of the practices and policies of major global public animal pharmaceutical companies and twelve of the largest quick-service restaurants in the US.
Regarding the Animal Pharmaceutical engagement, Anna seeks to understand how animal pharmaceutical companies may be addressing the risk of AMR. Her work focuses on exploring some of the key actions the companies must take to future-proof the long-term sustainability of their antibiotic portfolios, capitalise on the demand for alternatives to antibiotics, and reduce the spread of AMR.
Her work on the Restaurant Antibiotic engagement looks to improve disclosure around how companies are mitigating antimicrobial resistance (AMR) risk in the supply chains of their key animal proteins and ensuring the use of medically important antibiotics aligns with recommendations from the WHO.
Anna also supports the work of the Investor Action on AMR initiative in addressing the systemic risk of global antimicrobial resistance from a one health perspective.
Experience
Anna has a background in biomedical science with a particular focus on immunology and microbiology. Anna is passionate about sustainability and has previously managed content acquisition and editor engagement for academic journals publishing cutting edge research related to topics within sustainability.
